Filter

Refine by collections

  • Cardiovascular (2)

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 2 of 2 items for :

  • Cardiovascular x
Clear All
Mette Faurholdt Gude Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Search for other papers by Mette Faurholdt Gude in
Google Scholar
PubMed Close
,
Rikke Hjortebjerg Department of Molecular Endocrinology, University of Southern Denmark, Odense, Denmark
Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark

Search for other papers by Rikke Hjortebjerg in
Google Scholar
PubMed Close
,
Mette Bjerre Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Search for other papers by Mette Bjerre in
Google Scholar
PubMed Close
,
Morten Haaning Charles Department of Public Health, Aarhus University, Aarhus, Denmark
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Morten Haaning Charles in
Google Scholar
PubMed Close
,
Daniel R Witte Department of Public Health, Aarhus University, Aarhus, Denmark
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Daniel R Witte in
Google Scholar
PubMed Close
,
Annelli Sandbæk Department of Public Health, Aarhus University, Aarhus, Denmark
Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Annelli Sandbæk in
Google Scholar
PubMed Close
, and
Jan Frystyk Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark

Search for other papers by Jan Frystyk in
Google Scholar
PubMed Close

likely related to its ability to increase insulin-like growth factor-1 (IGF1) action. PAPP-A activates IGF1 through proteolytic cleavage of IGF-binding proteins (IGFBP) -2, -4 and -5, which provides IGFBP fragments with low ligand affinity. By this

Article Type:
Research Article
Collections:
Cardiovascular
DOI:
https://doi.org/10.1530/EC-22-0451
Volume/Issue:
Volume 12: Issue 3
Open access
Alicia Romano Department of Pediatrics, New York Medical College, Valhalla, New York, USA

Search for other papers by Alicia Romano in
Google Scholar
PubMed Close
,
Juan Pablo Kaski Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital & UCL Institute of Cardiovascular Science, London, UK

Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed Close
,
Jovanna Dahlgren Department of Paediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed Close
,
Nicky Kelepouris US Medical Affairs, Novo Nordisk Inc., Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed Close
,
Alberto Pietropoli Global Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland

Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed Close
,
Tilman R Rohrer Department of Pediatric Endocrinology, University Children’s Hospital, Saarland University Medical Center, Homburg, Germany

Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed Close
, and
Michel Polak Paediatric Endocrinology, Diabetology and Gynaecology Department, Hôpital Universitaire Necker Enfants-Malades, AP-HP, Université de Paris, Imagine Institute, Paris, France

Search for other papers by Michel Polak in
Google Scholar
PubMed Close

.31) 13 −2.57 (1.54) Bone age/chronological age 163 0.83 (0.19) 8 0.87 (0.10) IGF1 SDS (22) 162 −1.13 (1.62) 7 −1.22 (1.98) GH dose at baseline (mg/kg/day) 404 0.044 (0.014) 21 0.040 (0.019) GH-naïve at

Article Type:
Research Article
Collections:
Cardiovascular
DOI:
https://doi.org/10.1530/EC-21-0549
Volume/Issue:
Volume 11: Issue 1
Open access